ANDA 220041, held by Riconpharma LLC. Topiramate.
As of Nov 15, 2026, ANDA 220041 (Topiramate), held by Riconpharma LLC, was first approved by FDA on May 26, 2026, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 26, 2026 | Original application | Approved | None posted |
| Topiramate25MG · capsule, extended release;oral | Topiramate | Discontinued |
| Topiramate50MG · capsule, extended release;oral | Topiramate | Discontinued |
| Topiramate100MG · capsule, extended release;oral | Topiramate | Discontinued |
| Topiramate150MG · capsule, extended release;oral | Topiramate | Discontinued |
| Topiramate200MG · capsule, extended release;oral | Topiramate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters